X

Vous n'êtes pas connecté

Maroc Maroc - NEWS.MEDICAL.NET - A la Une - 11/09/2024 06:08

A promising new therapeutic target for MASLD identified

Using a novel stem cell platform, a team of the Medical University of South Carolina researchers has identified a pathway that could be targeted by drugs to reduce fat accumulation in patients with a common form of fatty liver disease known as metabolic dysfunction-associated steatotic liver disease, or MASLD.

Articles similaires

Do cocoa flavanols influence heart and fatty liver risk factors?

news.medical.net - 17/Feb 01:28

A recent Nutrients review examined whether cocoa-rich dark chocolate influences cardiovascular and metabolic dysfunction-associated steatotic liver...

Do cocoa flavanols influence heart and fatty liver risk factors?

news.medical.net - 17/Feb 01:28

A recent Nutrients review examined whether cocoa-rich dark chocolate influences cardiovascular and metabolic dysfunction-associated steatotic liver...

Hidden cholesterol crystals may quietly damage the liver, study finds

knowridge.com - 14/Feb 00:08

Scientists have discovered a new clue about why some people with fatty liver disease develop serious liver problems while others do not. A study from...

Hidden cholesterol crystals may quietly damage the liver, study finds

knowridge.com - 14/Feb 00:08

Scientists have discovered a new clue about why some people with fatty liver disease develop serious liver problems while others do not. A study from...

A mother’s diet may shape a child’s liver health for life

knowridge.com - 11/Feb 01:31

Fatty liver disease is becoming increasingly common in both adults and children, and scientists are trying to understand why some people develop it so...

How Mediterranean and MIND diets could protect against Alzheimer’s

knowridge.com - 17/Feb 00:42

Alzheimer’s disease is a common form of dementia that affects memory, thinking, and behavior. As the disease progresses, it can severely impact...

Adjuvant aumolertinib significantly improves disease-free survival after resection of EGFR-mutant NSCLC

oncologynews.com.au - 13/Feb 02:07

New data from the phase III ARTS trial published in The Lancet Oncology confirm that adjuvant aumolertinib significantly improves disease-free...

Adjuvant aumolertinib significantly improves disease-free survival after resection of EGFR-mutant NSCLC

oncologynews.com.au - 13/Feb 02:07

New data from the phase III ARTS trial published in The Lancet Oncology confirm that adjuvant aumolertinib significantly improves disease-free...